[Impact of positron emission tomography with FDG-PET in treatment of patients with suspected recurrent ovarian cancer].
OBJECTIVE
Recurrent ovarian cancer is a major problem and an accurate diagnosis can often change patients' management. This study aimed to assess the impact on management of FDG-PET in recurrent ovarian cancer.


METHODS
Forty-three patients in whom FDG-PET scan was performed due to suspected recurrent ovarian cancer were included. FDG-PET results were confirmed by histopathology and clinical follow-up of at least 12 months. To assess impact on management the treatment plan based on conventional imaging methods was compared with the treatment plan based on inclusion of PET findings, classifying FDG-PET impact on management as high, medium, low or no impact. Management changes, when present, were classified as intermodality or intramodality.


RESULTS
FDG-PET had a high impact on therapeutic management in 28 patients (65.1 %), medium impact in 2 patients (4.6 %), low impact in 9 patients (20.9 %), and no impact in 4 patients (9.3 %). FDG-PET induced an intermodality change in management in 27 patients (62,8 %); intramodality changes were induced in 3 patients (7 %). Finally, it produced no treatment changes in 13 patients (30.2 %).


CONCLUSIONS
FDG-PET supplied additional information when compared to conventional diagnostic procedures and allowed adequate management changes in most patients.
Ruiz-Hernández
G
G
Instituto PET FOCUSCAN S.L, Madrid. focuscan@teleline.es
Delgado-Bolton
R C
RC
Fernández-Pérez
C
C
Lapeña
L
L
Jiménez-Vicioso
A
A
Pérez-Castejón
M J
MJ
Domper
M
M
Montz
R
R
Carreras Delgado
J L
JL
D000328:Adult; D000368:Aged; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging*; D010051:Ovarian Neoplasms / Q000000981:diagnostic imaging* / Q000628:therapy*; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D012189:Retrospective Studies
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18